51. Parathyroid Hormone Treatment for Osteoporosis

  1. Clifford J. Rosen MD
  1. Felicia Cosman and
  2. Susan L. Greenspan

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch51

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Cosman, F. and L. Greenspan, S. (2013) Parathyroid Hormone Treatment for Osteoporosis, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch51

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • antiresorptive agents;
  • monotherapy;
  • osteoporosis;
  • parathyroid hormone (PTH) treatment

Summary

Parathyroid hormone (PTH) is a unique approach to osteoporosis treatment. This chapter reviews the clinical trial data using PTH as both monotherapy and in combination and sequential regimens with antiresorptive agents in women and men. It briefly overviews trials in a few special populations. PTH should be recommended for individuals who have been on prior antiresorptive agents, and who have had a suboptimal response to treatment, defined as incident fractures or active bone loss during therapy, or who have persistent osteoporosis despite therapy. PTH may be able to ensure more long-term protection against fracture occurrence than antiresorptive agents alone.